WHO website linked below states that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic, so as to fast track the vaccine for when it is needed.
In Europe, some manufacturers have conducted advance studies using a so-called "mock-up" vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus.
According to the website, “Such advance studies can greatly expedite regulatory approval.”
Sources:
World Health Organization
http://www.who.int/csr/disease/swineflu/notes/h1n1_safety_vaccines_20090805/en/index.html
In Europe, some manufacturers have conducted advance studies using a so-called "mock-up" vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus.
According to the website, “Such advance studies can greatly expedite regulatory approval.”
Sources:
World Health Organization
http://www.who.int/csr/disease/swineflu/notes/h1n1_safety_vaccines_20090805/en/index.html
